About Osteoporosis
Osteoporosis is a disease that reduces of the mass and density of bone, and results in increased risk of fracture. In this disease, the risks related to fracture increases because of the increased permeability of the bones. Often, there are no symptoms observed until the first fracture occurs. Increase in age, low body weight, low sex hormones or menopause, and smoking are some of the risk factors associated with this disease.
TechNavio's analysts forecast the Osteoporosis Drugs market in APAC to grow at a CAGR of 4.73 percent over the period 2014-2019.
Covered in this Report
The Osteoporosis Drugs market in APAC can be divided into two segments: Antiresorptives and Anabolics. This report covers the present scenario and the growth prospects of the Osteoporosis Drugs market in APAC for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various osteoporosis drugs that are available in the market.
TechNavio's report, the Osteoporosis Drugs market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Osteoporosis Drugs market in APAC landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors
• Amgen
• Eli Lilly
• Merck
• Novartis
Other Prominent Vendors
• F. Hoffmann La Roche
• GlaxoSmithKline
• Jiangsu Hengrui Medicine
• Pfizer Inc.
• Qingdao Chiatai Haier Pharmaceutical ?
Market Driver
• Increasing Global Aging Population
• For a full, detailed list, view our report
Market Challenge
• Multiple Patent Expiries
• For a full, detailed list, view our report
Market Trend
• Increasing Awareness of Bone Health Education
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Pipeline Snapshot
08. Epidemiology and Demography
08.1.1 China
08.1.2 Hong Kong
08.1.3 Japan
08.1.4 India
09. Market Segmentation by Drug Class
10. Market Assessment of Top Drugs
10.1 Prolia
10.1.1 Sales
10.2 Fosamax
10.2.1 Sales
10.3 Evista
10.3.1 Sales
10.4 Forteo
10.4.1 Sales
10.5 Zometa
10.5.1 Sales
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Amgen
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation by Revenue 2013
19.1.4 Product Portfolio by Revenue 2013
19.1.5 Business Segmentation by Revenue 2012 and 2013
19.1.6 Geographical Segmentation by Revenue 2013
19.1.7 Business Strategy
19.1.8 Recent Developments
19.1.9 SWOT Analysis
19.2 Eli Lilly
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation by Revenue
19.2.4 Sales by Geography
19.2.5 Business Strategy
19.2.6 Key Information
19.2.7 SWOT Analysis
19.3 Merck & Co. Inc.
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation by Revenue 2013
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Sales by Geography
19.3.6 Business Strategy
19.3.7 Key Developments
19.3.8 SWOT Analysis
19.4 Novartis AG
19.4.1 Key Facts
19.4.2 Business Description
19.4.3 Business Segmentation
19.4.4 Revenue by Business Segmentation
19.4.5 Revenue Comparison 2012 and 2013
19.4.6 Sales by Geography
19.4.7 Business Strategy
19.4.8 Key Developments
19.4.9 SWOT Analysis
20. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Osteoporosis Drugs Market in APAC 2013-2018 (US$ billion)
Exhibit 3: Clinical Trial Map of Conjugated Estrogens/Bazedoxifene
Exhibit 4: Clinical Trial Map of Viviant
Exhibit 5: Clinical Trial Map of Prolia
Exhibit 6: Clinical Trial Map of Romosozumab
Exhibit 7: Clinical Trial Map of LY2541546 (Blosozumab)
Exhibit 8: Population Increase in People Aged 50 Years Or Over By Country (million), 2013 to 2019
Exhibit 9: Osteoporosis Drugs Market in APAC Segmentation by Drug Class
Exhibit 10: Antiresorptives Drugs Segmentation
Exhibit 11: Bisphosphonates Drugs Segmentation
Exhibit 12: Amgen's Prolia Global Revenue 2010-2013 (US$ million)
Exhibit 13: Merck's Fosamax Global Revenue 2009-2012 (US$ million)
Exhibit 14: Eli Lilly's Evista Global Revenue 2010-2013 (US$ million)
Exhibit 15: Eli Lilly's Forteo Global Revenue 2010-2013 (US$ million)
Exhibit 16: Novartis Zometa Global Revenue 2010-2013 (US$ million)
Exhibit 17: Amgen: Business Segmentation by Revenue 2013
Exhibit 18: Amgen: Product Portfolio by Revenue 2013
Exhibit 19: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 20: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 21: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 22: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 23: Eli Lilly: Sales by Geography 2013
Exhibit 24: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 25: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 26: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 27: Novartis AG: Business Segmentation
Exhibit 28: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 29: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 30: Novartis AG: Revenue by Geographical Segmentation 2013
